Revvity adds FDA-cleared total testosterone assay to ChLIA menu

Revvity said on May 13, 2026, that the FDA cleared its automated chemiluminescence immunoassay, or ChLIA, for total testosterone, adding it to the company’s existing FDA-cleared assays for free testosterone and sex hormone-binding globulin, or SHBG. The company says that makes its IDS platform the first FDA-cleared ChLIA portfolio to directly measure all three analytes on a single automated system, aimed at workups for testosterone-related disorders, including suspected hypogonadism. Revvity also said the assay runs on its IDS random-access automation platforms and is designed to simplify lab workflow compared with more complex equilibrium dialysis and LC-MS methods. (news.revvity.com)

Why it matters: For veterinary professionals, this is mainly a human diagnostics development, not a veterinary-specific clearance. Still, it’s a useful signal about where endocrine testing is heading: toward more automated, integrated hormone panels with faster turnaround and less technical complexity. That matters because testosterone testing has long faced concerns around assay standardization, accuracy, and workflow burden, especially when compared with reference-style methods such as equilibrium dialysis and mass spectrometry. (news.revvity.com)

What to watch: Watch for whether Revvity publishes more performance data, secures broader lab adoption, or expands the platform’s endocrine menu further in the months ahead. (news.revvity.com)